HDAC9 and idiopathic pulmonary fibrosis: HDAC6 inhibitors (trichostatin A [TSA]), TSA is classified in Class 1/2 or pan HDAC inhibitor, are innovative and targeted disease-modifying agents in rare diseases, including IPF (Brindisi et al., 2020).